Tauber E - Search Results

1

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.

Reisinger EC, Tschismarov R, Beubler E, Wiedermann U, Firbas C, Loebermann M, Pfeiffer A, Muellner M, Tauber E, Ramsauer K. Reisinger EC, et al. Among authors: tauber e. Lancet. 2019 Dec 22;392(10165):2718-2727. doi: 10.1016/S0140-6736(18)32488-7. Epub 2018 Nov 5. Lancet. 2019. PMID: 30409443 Clinical Trial.

2

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.

Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A, Dewasthaly S, Klade CS. Tauber E, et al. Lancet. 2007 Dec 1;370(9602):1847-53. doi: 10.1016/S0140-6736(07)61780-2. Lancet. 2007. PMID: 18061060 Clinical Trial.

3

Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.

Ramsauer K, Schwameis M, Firbas C, Müllner M, Putnak RJ, Thomas SJ, Desprès P, Tauber E, Jilma B, Tangy F. Ramsauer K, et al. Among authors: tauber e. Lancet Infect Dis. 2015 May;15(5):519-27. doi: 10.1016/S1473-3099(15)70043-5. Epub 2015 Mar 2. Lancet Infect Dis. 2015. PMID: 25739878 Clinical Trial.

4

Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections.

Schrauf S, Tschismarov R, Tauber E, Ramsauer K. Schrauf S, et al. Among authors: tauber e. Front Immunol. 2020 Apr 9;11:592. doi: 10.3389/fimmu.2020.00592. eCollection 2020. Front Immunol. 2020. PMID: 32373111 Free PMC article. Review.

5

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.

Tauber E, Kollaritsch H, von Sonnenburg F, Lademann M, Jilma B, Firbas C, Jelinek T, Beckett C, Knobloch J, McBride WJ, Schuller E, Kaltenböck A, Sun W, Lyons A. Tauber E, et al. J Infect Dis. 2008 Aug 15;198(4):493-9. doi: 10.1086/590116. J Infect Dis. 2008. PMID: 18588481 Clinical Trial.

6

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS. Firbas C, et al. Among authors: tauber e. Vaccine. 2006 May 15;24(20):4343-53. doi: 10.1016/j.vaccine.2006.03.009. Epub 2006 Mar 20. Vaccine. 2006. PMID: 16581161 Clinical Trial.

7

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.

Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, Kollaritsch H, Paulke-Korinek M, von Sonnenburg F, Spruth M, Tauber E, Wiedermann U, Schuller E. Kaltenböck A, et al. Among authors: tauber e. Vaccine. 2009 Jul 16;27(33):4483-9. doi: 10.1016/j.vaccine.2009.05.034. Epub 2009 May 30. Vaccine. 2009. PMID: 19486955 Clinical Trial.

8

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study.

Schuller E, Klade CS, Wölfl G, Kaltenböck A, Dewasthaly S, Tauber E. Schuller E, et al. Among authors: tauber e. Vaccine. 2009 Mar 26;27(15):2188-93. doi: 10.1016/j.vaccine.2008.12.062. Epub 2009 Feb 4. Vaccine. 2009. PMID: 19200452 Clinical Trial.

9

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenböck A, Klade C, Tauber E. Schuller E, et al. Among authors: tauber e. Vaccine. 2008 Aug 12;26(34):4382-6. doi: 10.1016/j.vaccine.2008.05.081. Epub 2008 Jun 17. Vaccine. 2008. PMID: 18599165 Clinical Trial.

10

Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.

Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, Thursz M, Zeuzem S, Hofmann WP, Hinrichsen H, Tauber E, Manns MP, Klade CS. Wedemeyer H, et al. Among authors: tauber e. Vaccine. 2009 Aug 13;27(37):5142-51. doi: 10.1016/j.vaccine.2009.06.027. Epub 2009 Jun 24. Vaccine. 2009. PMID: 19559112 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

134 results

Search Page